Ebola-specific therapeutic antibodies from lab to clinic: The example of ZMapp

In the 1990s, monoclonal antibodies (mAbs) progressed from scientific tools to advanced therapeutics, particularly for the treatment of cancers and autoimmune and inflammatory disorders. In the arena of infectious disease, the inauguration of mAbs as a post-exposure treatment in humans against Ebola...

Full description

Saved in:

Bibliographic Details
Published in:	Antiviral research Vol. 226; p. 105873
Main Authors:	Wong, Gary, Bienes, Kathrina Mae, XIII, Ara, Fausther-Bovendo, Hugues, Kobinger, Gary P.
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 01.06.2024
Subjects:	Africa, Western - epidemiology Animals Antibodies, Monoclonal - immunology Antibodies, Monoclonal - therapeutic use Antibodies, Neutralizing - immunology Antibodies, Neutralizing - therapeutic use Antibodies, Viral - immunology Antibodies, Viral - therapeutic use Disease Outbreaks Ebola Virus Ebolavirus - drug effects Ebolavirus - immunology EBOV Hemorrhagic Fever, Ebola - drug therapy Hemorrhagic Fever, Ebola - immunology Humans mAbs Monoclonal antibodies ZMapp Africa, Western Monoclonal antibodies EBOV Ebola Virus ZMapp mAbs
ISSN:	0166-3542, 1872-9096, 1872-9096
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!